Genetic or pharmacologic blockade of mPGES-2 attenuates renal lipotoxicity and diabetic kidney disease by targeting Rev-Erbα/FABP5 signaling.
Published:1 April 2024
DOI: 10.1016/j.celrep.2024.114075
Abstract




